Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

End-of-life therapy: palliative care instead of palliative scare

End-of-life therapy: palliative care instead of palliative scare editorial memo (2020) 13:7–8 https://doi.org/10.1007/s12254-019-00561-4 Eva Katharina Masel Received: 6 December 2019 / Accepted: 10 December 2019 © Springer-Verlag GmbH Austria, part of Springer Nature 2020 In this issue of memo, a series of short reviews up- the management of delirium, death rattle and dysp- date important issues concerning end-of-life care of nea, palliative sedation, psilocybin as a potential drug patients suffering from incurable diseases. Palliative to reduce the fear of death and denial as a coping care aims to provide symptom control, relieve anxi- mechanism. Also, deprescribing drugs is mentioned ety and depression and also decrease stress levels of as an important skill in palliative care. patients and their relatives. Roider-Schur [7] focuses on palliative sedation for Jahn-Kuch [1] gives an overview on how to avoid delirium management. With a prevalence that ranges late cancer-directed therapy in terminally ill cancer from 20 to 40% and up to 90% in the end-of-life phase, patients. This remains challenging, as survival rates delirium is a frequent neurocognitive impairment in have improved in recent decades while treatment of patients suffering from cancer. Palliative sedation is cancer patients near death is becoming increasingly known not to shorten life and should be regarded as http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

End-of-life therapy: palliative care instead of palliative scare

Download PDF
2 pages

Loading next page...
 
/lp/springer-journals/end-of-life-therapy-palliative-care-instead-of-palliative-scare-KQs0d5awGM

References (14)

Publisher
Springer Journals
Copyright
Copyright © Springer-Verlag GmbH Austria, part of Springer Nature 2020
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-019-00561-4
Publisher site
See Article on Publisher Site

Abstract

editorial memo (2020) 13:7–8 https://doi.org/10.1007/s12254-019-00561-4 Eva Katharina Masel Received: 6 December 2019 / Accepted: 10 December 2019 © Springer-Verlag GmbH Austria, part of Springer Nature 2020 In this issue of memo, a series of short reviews up- the management of delirium, death rattle and dysp- date important issues concerning end-of-life care of nea, palliative sedation, psilocybin as a potential drug patients suffering from incurable diseases. Palliative to reduce the fear of death and denial as a coping care aims to provide symptom control, relieve anxi- mechanism. Also, deprescribing drugs is mentioned ety and depression and also decrease stress levels of as an important skill in palliative care. patients and their relatives. Roider-Schur [7] focuses on palliative sedation for Jahn-Kuch [1] gives an overview on how to avoid delirium management. With a prevalence that ranges late cancer-directed therapy in terminally ill cancer from 20 to 40% and up to 90% in the end-of-life phase, patients. This remains challenging, as survival rates delirium is a frequent neurocognitive impairment in have improved in recent decades while treatment of patients suffering from cancer. Palliative sedation is cancer patients near death is becoming increasingly known not to shorten life and should be regarded as

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Mar 3, 2020

There are no references for this article.